Cuba backs Brazil in AIDS drug patent row

7 March 2001

The government of Cuba has declared its support for Brazil in its battlewith the USA over the latter's claim, which is currently the subject of World Trade Organization arbitration action, that Brazil's 1997 patent legislation discriminates against imported drugs (Marketletter February 12).

A statement from Cuba's Foreign Ministry said that Brazil's argument that it has the right to manufacture cheaper generic versions of imported HIV/AIDS treatments would contribute to "broader and sounder solutions in the fight against AIDS," according to Reuters reports.

"It is unacceptable that commercial interests, technicalities or the desire for profit be pitted against the right of the people to find solutions to disease that constitute a source of humanity," the Ministry statement added. It went on to criticize pharmaceutical majors for "seeking huge profits, where the lives and suffering of millions of people are at stake," and said that the USA was "once more siding with those whose interest in excessive profits clashes with vital human interests, including the most basic right to life."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight